MR Imaging Features Predictive of Pathologic Complete Response and Survival Outcomes for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Abstract

Purpose: This study aims to evaluate the predictive value of MRI features for pathologic complete response (pCR) and survival outcomes in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NAC).

Methods: A retrospective analysis was conducted on 168 BC patients treated with NAC between 2018 and 2022. Pre-NAC breast MRI scans were evaluated for enhancement patterns, time-intensity curve (TIC), peritumoral edema, and background enhancement. Both pre- and post-NAC MRIs were assessed for Epeak %, mean apparent diffusion coefficient (ADC) value, and ADC ratio (mean ADC of lesion/contralateral normal breast parenchyma). Survival outcomes were analyzed using Kaplan-Meier and Cox regression models.

Results: pCR was achieved in 34% of patients. MRI demonstrated a sensitivity of 74% and a specificity of 86% in predicting pCR, with an overall accuracy of 82%. The post-NAC percentage of initial peak enhancement (Epeak) was significantly lower in the pCR group (P < 0.001). Multivariate analysis identified a pre-NAC Epeak ≤ 96 (hazard ratio [HR]: 6.26, P < 0.001) and a post-NAC Epeak > 188 (HR: 18.40, P < 0.001) as independent risk factors for disease-free survival. Additionally, a lower pre-NAC ADC ratio (≤0.65) was associated with poorer overall survival (HR: 2.8, P: 0.041). Pre-NAC peritumoral edema, background enhancement, and TIC were not significant predictors of survival outcomes.

Conclusion: MRI features, including Epeak % and ADC ratio, are important predictors of pCR and survival outcomes in BC patients undergoing NAC. Incorporating these biomarkers into clinical practice may improve treatment planning and optimize patient outcomes.